SYN125 / Synermore - LARVOL DELTA

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions (clinicaltrials.gov) - P1 | N=22 | Active, not recruiting | Sponsor: Synermore Biologics Co., Ltd. | Recruiting ➔ Active, not recruiting | N=36 ➔ 22 | Trial completion date: May 2022 ➔ Sep 2023 | Trial primary completion date: Feb 2022 ➔ Jul 2023

Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • EGFR

A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body. (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Synermore Biologics Co., Ltd.; Trial completion date: Dec 2021 ➔ May 2022; Trial primary completion date: Sep 2021 ➔ Feb 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • EGFR

A Study to Find the Maximum Tolerated Dose of SYN125 in People With Advanced Colorectal and Head and Neck Cancer (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Synermore Biologics Co., Ltd.

Clinical • Combination therapy • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck